Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
G Comi, V Martinelli, M Rodegher, L Moiola, O Bajenaru, A Carra, I Elovaara, F Fazekas, HP Hartung, J Hillert, J King, S Komoly, C Lubetzki, X Montalban, KM Myhr, M Ravnborg, P Rieckmann, D Wynn, C Young, M Filippi Show all
The Lancet | Published : 2009
BACKGROUND: Glatiramer acetate, approved for the treatment of relapsing-remitting multiple sclerosis, reduces relapses and disease activity and burden monitored by MRI. We assessed the efficacy of early treatment with glatiramer acetate in delaying onset of clinically definite multiple sclerosis. METHODS: In this randomised, double-blind trial, undertaken in 80 sites in 16 countries, 481 patients presenting with a clinically isolated syndrome with unifocal manifestation, and two or more T2-weighted brain lesions measuring 6 mm or more, were randomly assigned to receive either subcutaneous glatiramer acetate 20 mg per day (n=243) or placebo (n=238) for up to 36 months, unless they converted t..View full abstract